Quick Answer
60 DEGREES PHARMACEUTICALS, INC. reported Operating Income of -$7.76 million for fiscal year 2025.
60 DEGREES PHARMACEUTICALS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$7.76M | +20.1% |
| 2024 | -$9.72M | -88.5% |
| 2023 | -$5.15M | -194.5% |
| 2022 | -$1.75M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.33M | -9.8% | -44.9% |
| June 30, 2025 | -$1.60M | +61.7% | +16.0% |
| March 31, 2025 | -$1.91M | -42.3% | +9.8% |
| September 30, 2024 | -$2.12M | -39.2% | +49.4% |
| June 30, 2024 | -$4.19M | -431.6% | -212.0% |
| March 31, 2024 | -$1.34M | -41.2% | +11.8% |
| September 30, 2023 | -$1.52M | -607.4% | -93.1% |
| June 30, 2023 | -$788.0K | -14.7% | +17.1% |
- 60 DEGREES PHARMACEUTICALS, INC. showed an increase of +20.1% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, 60 DEGREES PHARMACEUTICALS, INC.’s operating income has declined by 343.2% (from -$1.75 million to -$7.76 million).
- The most recent figure is from 60 DEGREES PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: